A phase I clinical trial was conducted in patients with glypican-3 (GPC3) and mesothelin (MSLN)-positive advanced hepatocellular carcinoma (HCC), pancreatic cancer (PC), and ovarian cancer (OC) [45]. This evidence concerns the gene MSLN and pachyonychia congenita.